Related references
Note: Only part of the references are listed.Conversion to Aflibercept For Chronic Refractory Or Recurrent Neovascular Age-Related Macular Degeneration
Yoshihiro Yonekawa et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2013)
Short-Term Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Treated With Other Vascular Endothelial Growth Factor Inhibitors
Vincent Y. Ho et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2013)
Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab
Benjamin Bakall et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2013)
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
Hyung Cho et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2013)
Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab
K. H. Patel et al.
EYE (2013)
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Usha Chakravarthy et al.
LANCET (2013)
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Soraya Rofagha et al.
OPHTHALMOLOGY (2013)
VISUAL AND ANATOMICAL OUTCOMES OF INTRAVITREAL AFLIBERCEPT IN EYES WITH PERSISTENT SUBFOVEAL FLUID DESPITE PREVIOUS TREATMENTS WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Nishant Kumar et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation
Julie L. Gasperini et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab
Maria Salling Eghoj et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?
Susanne Binder
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Daniel F. Martin et al.
OPHTHALMOLOGY (2012)
Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis
Farzin Forooghian et al.
ACTA OPHTHALMOLOGICA (2011)
INTRAOCULAR PHARMACOKINETICS AFTER A SINGLE INTRAVITREAL INJECTION OF 1.5 MG VERSUS 3.0 MG OF BEVACIZUMAB IN HUMANS
Carsten H. Meyer et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2011)
NOVEL METHOD FOR ANALYZING SNELLEN VISUAL ACUITY MEASUREMENTS
Ninel Z. Gregori et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2010)
Is There Tachyphylaxis to Intravitreal Anti-Vascular Endothelial Growth Factor Pharmacotherapy in Age-Related Macular Degeneration?
Shlomit Schaal et al.
OPHTHALMOLOGY (2008)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
